About IMVARIA
IMVARIA is a health tech company pioneering AI-driven digital biomarker solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease and reduce the need for invasive biopsy testing. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates its AI Lab and Digital Biomarker Lab with automated, machine-learning algorithm technology to transform clinical decision-making into data science.
Based in Berkeley, CA, IMVARIA focuses on serious diseases such as lung fibrosis and interstitial lung disease. Their flagship products include Fibresolve and ScreenDx, the first FDA-authorized AI tools in ILD and IPF. Fibresolve provides non-invasive AI biomarker diagnostic support for idiopathic pulmonary fibrosis, while ScreenDx assists in screening for interstitial lung disease. IMVARIA also collaborates with healthcare institutions like Mayo Clinic to advance AI digital biomarker research in cancer.
IMVARIA's mission is to harness artificial intelligence to improve clinical assessments and patient outcomes by delivering precise, data-driven insights for better decision-making and optimized therapeutic development.
Key Products and Solutions
- Fibresolve: An FDA Breakthrough Designated and authorized software-as-medical-device that non-invasively classifies lung fibrosis subtypes to assist clinicians in diagnosing idiopathic pulmonary fibrosis (IPF).
- ScreenDx: An FDA-cleared AI-powered screening algorithm that automatically assesses CT imaging data for interstitial lung disease to enhance referral pathways and early diagnosis.
- Bronchosolve (investigational): An AI tool under research for assessing lung nodule risk in screening cases.
Clinical and Research Collaboration
IMVARIA collaborates with leading institutions such as Mayo Clinic and Stanford Medicine to improve disease understanding and validate their AI solutions. Their AI biomarkers are featured in major conferences like the American Thoracic Society International Conference. Clinical data and research abstracts are published in various prestigious medical journals, reinforcing IMVARIA’s commitment to advancing AI in healthcare.
IMVARIA is a remote-first company, expanding its engineering and commercial teams to build and deploy medical-grade AI software platforms for lung disease and beyond.